Business
Curis Provides Fourth Quarter 2025 Business Update
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025.
About this update from Curis, Inc.
[{"type":"text","content":"Management to host conference call today at 4:30 p.m. ET","length":56,"tagName":"p","attribs":{}},{"type":"text","content":"LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025.","length":313,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Curis, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Curis, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":207,"url":"https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c4huai0TNttEc06IqqxyOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2NQ--/https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a","width":400,"height":207}},"href":"https://mma.prnewswire.com/media/607886/Curis_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Operational Highlights","length":22,"tagName":"p"},{"type":"text","content":"TakeAim Lymphoma","length":16,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Lakshmi Nayak, MD, Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston, presented a poster with updated clinical data in Primary CNS Lymphoma (PCNSL) at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) in November 2025. The poster, titled Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients, showed results for 24 patients who have received treatment with emavusertib and ibrutinib, a BTK inhibitor (BTKi), for at least 1 cycle (28 days):","length":595,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"5 of 5 BTKi-naïve patients achieved objective response (100% ORR)","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"7 of 19 BTKi-experienced patients achieved objective response (37% ORR)","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Median treatment duration for the 12 responders was 123 days (44 – 798 days)","length":76,"tagName":"p"}]},{"val":[{"type":"text","co...